GlassScriptPhysician profile
Barry J Gordon
NPI 1063515443
$2,553.46
in general payments reported to CMS, 2019-2025
15 companies · $475 in 2025
The $475 reported for 2025 was less than what a typical Neuromuscular Medicine (Psychiatry & Neurology) provider received nationally (typical 2025 total: $530).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $976 · 2020: $11.16 · 2021: $62.23 · 2022: $377 · 2023: $431 · 2024: $220 · 2025: $475.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,126.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,126.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,152.65 | 2022-2025 | |
| Allergan, INC. | $292.74 | 2019-2021 | |
| Amgen INC. | $236.42 | 2019 | |
| Akcea Therapeutics, INC. | $160.68 | 2019-2020 | |
| Lilly USA, LLC | $122.04 | 2025 | Kisunla |
| Biogen, INC. | $110.36 | 2019-2021 | |
| Axogen | $110.31 | 2023 | Avance Nerve Graft |
| Acadia Pharmaceuticals INC | $103.59 | 2019 | |
| Ucb, INC. | $87.23 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $44.60 | 2022 | |
| Livanova USA, INC. | $36.21 | 2019 | |
| Sumitomo Pharma America, INC. | $28.41 | 2024 | Orgovyx |
| Astellas Pharma US INC | $22.95 | 2025 | Xtandi |
| Novartis Pharmaceuticals Corporation | $22.64 | 2019 | |
| Impel Pharmaceuticals INC. | $22.63 | 2023 | Trudhesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barry Gordon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.